Texas § 491.055 CONTRACT WITH LEAD INSTITUTION.

Texas Statutes

§ 491.055 — CONTRACT WITH LEAD INSTITUTION.

Texas § 491.055

Code HSHealth and Safety Code

This text of Texas § 491.055 (CONTRACT WITH LEAD INSTITUTION.) is published on Counsel Stack Legal Research, covering Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tex. Health and Safety Code Code Ann. § 491.055 (2026).

Text

Sec. 491.055. CONTRACT WITH LEAD INSTITUTION.

(a)As soon as practicable after selecting a consortium to conduct ibogaine drug development clinical trials under Section 491.054 , the commission shall enter into an interagency contract, as provided by Chapter 771 , Government Code, with the lead institution of higher education of the selected consortium to provide funding to implement the consortium's proposed ibogaine drug development clinical trials.

(b)The interagency contract described by Subsection (a) must specify:

(1)the goals and objectives of the proposed ibogaine drug development clinical trials;

(2)the proposed budget;

(3)the timeline for completing the proposed objectives;

(4)the for-profit, nonprofit, or public benefit corporate entities collaborating with the consortium i

Free access — add to your briefcase to read the full text and ask questions with AI

Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As soon as practicable after selecting a consortium to conduct ibogaine drug development clinical trials under Section 491.054 , the commission shall enter into an interagency contract, as provided by Chapter 771 , Government Code, with the lead institution of higher education of the selected consortium to provide funding to implement the consortium's proposed ibogaine drug development clinical trials.
(b) The interagency contract described by Subsection (a) must specify:
(1) the goals and objectives of the proposed ibogaine drug development clinical trials;
(2) the proposed budget;
(3) the timeline for completing the proposed objectives;
(4) the for-profit, nonprofit, or public benefit corporate entities collaborating with the consortium in the drug development clinical trials under this subchapter;
(5) the percentage of the revenue arising from the drug development clinical trials to be paid to the state; and
(6) any other information required by the commission.
(c) As soon as practicable after entering into an interagency contract under Subsection (a), the commission shall report the existence of the contract to the legislature.
(d) The commission may not disburse funds to or for a selected consortium under the interagency contract described by Subsection (a) until the consortium receives and the commission verifies the receipt of matching funds from sources other than the state.